币界网报道：An ASX-listed biotech firm, Race Oncology, has announced plans to allocate up to 10% of its cash reserves into Bitcoin as part of a new treasury strategy. The company, which focuses on cancer treatments, revealed the move in a filing with the Australian Securities Exchange (ASX), citing Bitcoin's potential as a hedge against inflation and currency devaluation. Race Oncology's CEO, Daniel Tillett, stated that the decision reflects the firm's commitment to maximizing shareholder value through diversified investments. The company holds approximately $26 million in cash reserves, meaning its Bitcoin investment could reach $2.6 million. This follows a growing trend of publicly traded companies, including MicroStrategy and Tesla, adding Bitcoin to their balance sheets. Race Oncology emphasized that the investment will be carefully managed to mitigate volatility risks. The announcement comes as Bitcoin's price shows signs of recovery, trading above $43,000 at the time of disclosure.